This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Collins, J. J. Articles by Franz, D. N. Search for Related Content PubMed PubMed Citation Articles by Collins, J. J. Articles by Franz, D. N. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Seizures Tuberous Sclerosis Social Bookmarking                         What's this?

Levetiracetam as Adjunctive Antiepileptic Therapy for Patients with Tuberous Sclerosis Complex: A Retrospective Open-Label Trial

From the Department of Neurology, Division of Pediatric Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Cynthia Tudor, MSN

From the Department of Neurology, Division of Pediatric Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Jennifer M. Leonard, MSN

From the Department of Neurology, Division of Pediatric Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Gail Chuck, BS

From the Department of Neurology, Division of Pediatric Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

David Neal Franz, MD

Department of Neurology, Cincinnati Children's Hospital Medical Center, ML 2015, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, david.franz{at}cchmc.org.

Seizures are a common neurologic symptom of tuberous sclerosis complex. The use of levetiracetam as adjunctive antiepileptic therapy was assessed in 20 patients with tuberous sclerosis complex aged 2 to 19 years. In this retrospective evaluation, 40% of patients treated with levetiracetam achieved a seizure reduction of more than 50%. Levetiracetam was generally well tolerated, and adverse events were relatively uncommon in patients who responded to treatment. The most commonly reported adverse events were behavioral problems. Unstable gait, insomnia, poor appetite, and increased seizure frequency were also reported. Based on these results, the use of levetiracetam as adjunctive antiepileptic therapy can reduce seizure frequency in patients with tuberous sclerosis complex. (J Child Neurol 2006;21:53—57).

Journal of Child Neurology, Vol. 21, No. 1, 53-57 (2006)
DOI: 10.1177/08830738060210011201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. D'Agati, R. Moavero, C. Cerminara, and P. Curatolo Attention-Deficit Hyperactivity Disorder (ADHD) and Tuberous Sclerosis Complex J Child Neurol, October 1, 2009; 24(10): 1282 - 1287. [Abstract] [PDF]